QALYs and Utilities: What Payers Mean by Value and Where the Numbers Come From

The quality-adjusted life year looks simple: time lived, weighted by the quality of that time. In practice, the utility values behind it are among the most scrutinised inputs in any economic model.

The basic idea

A QALY combines length and quality of life in one measure. Each health state is given a utility value on a scale where 1 represents full health and 0 represents death, and values below zero are possible for states considered worse than death. A year spent in a state with a utility of 0.7 counts as 0.7 QALYs. Differences in QALYs between treatments, set against differences in cost, produce the incremental cost-effectiveness ratio.

Where utilities come from

  • Generic preference-based instruments such as the EQ-5D, collected in trials and converted using a population-based value set.
  • Mapping from disease-specific questionnaires when no preference-based measure was collected, which adds statistical uncertainty.
  • Published literature, often the fallback, which can be inconsistent in method and population.
  • Vignette or time-trade-off studies when other sources are unavailable.

HTA bodies tend to favour utilities that were measured in the relevant patients, with value sets from the country concerned or a recognised alternative.

Why they cause disagreement

  • Instrument choice: different instruments can produce different values for the same patients.
  • Insensitivity: generic measures can miss what matters in some conditions, including some rare and paediatric diseases.
  • Age and comorbidity: without adjustment, utilities can overstate health in older populations.
  • Treatment-specific effects: administration burden or side effects may not be captured in the main state values.

Countries use the QALY differently

Not every system relies on a cost-per-QALY threshold, and discount rates, accepted instruments and preferred perspectives differ. The EU joint clinical assessment itself does not include economic evaluation, so QALY-based arguments remain a national matter. Check the requirements of each target market rather than assuming one model transfers.

Plan to collect the data

The cheapest utility data are those you collect in the trial. Including a preference-based instrument at suitable time points, and thinking about how it will be analysed, avoids reliance on weak mapping or literature values later. Where the generic instrument is likely to miss important effects, say so and plan supportive evidence.

A short checklist

  • Which instrument will be used to collect utilities, and at which visits?
  • Which value set will convert responses, and will target markets accept it?
  • If the data are missing, what is the backup source, and how will uncertainty be shown?
  • Are utility assumptions consistent between the model, the dossier and any publications?

Consistent answers here save a surprising amount of correspondence with assessors later.

How PQRA helps

PQRA does not build economic models, but we help companies connect regulatory planning to the evidence payers will need, including prompting early discussion of patient-reported and quality-of-life data collection across the development programme.

Ready to discuss your market access plan? Contact PQRA to talk through your product and your target markets.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *